Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended): A process ~~Process~~ for modifying the crystal habit of an acicular drug substance comprising suspending said crystalline drug substance in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.

Claim 2. (Currently amended): A process ~~Process~~ for recrystallising an acicular drug substance comprising suspending said crystals in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.

Claim 3. (Currently amended): A process ~~Process~~ according to claim 1 ~~or 2~~ wherein the crystal habit is modified in that the mean aspect ratio of the processed crystals is smaller than about 10:1.

Claim 4. (Currently amended): A process ~~Process~~ according to ~~any one of~~ claims 1 ~~to 3~~ wherein the drug substance after temperature oscillation has a bulk density of about above 200 kg/m^3.

Claim 5. (Currently amended): A process ~~Process~~ according to ~~any preceding~~ claim 1 wherein the temperature oscillation is in form of a zig-zag curve.

Claim 6. (Currently amended): A process according to ~~any one of~~ claims 1 ~~to 5 for producing crystals having~~ wherein the crystals produced have a mean aspect ratio of the processed crystals smaller than about 10:1 or a bulk density of about 200 kg/m^3.

Claim 7. (Original): Crystals of an acicular drug substance with an aspect ratio of about 10:1 to 1:1 and/or a bulk density of above about 200 kg/m^3.

Claim 8. (Original): Crystals according to claim 7 wherein the acicular drug substance is mycophenolic acid, or a mycophenolate salt.

Claim 9. (Currently amended): A pharmaceutical composition~~, e.g.~~ in the form of tablets, comprising crystals of claim 7 ~~or 8~~ in association with a pharmaceutically acceptable carrier.

Claim 10. (Original): Crystals of claim 8 for use as a pharmaceutical.

Claim 11. (Original): A crystal modification of mycophenolic acid or mycophenolate sodium having one of the following characteristic crystal structures, determined by means of an X-ray single crystal analysis, or having an X-ray powder diffraction pattern as defined below:

a) mycophenolate sodium anhydrate, modification A;

crystal system:	monoclinic
space group:	$P2_1/c$
a:	16.544(4)
b:	4.477(1)
c:	21.993(3)
ß:	92.14(1)°
V:	1627.8(6)
Z:	4
cal. Density:	1.397 g/cm^3

b) mycophenolate sodium hydrate;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 2;

c) hemisalt of mycophenolate sodium anhydrate;

crystal system:	triclinic
space group:	P-1
a:	11.172(6)
b:	12.020(6)
c:	13.441(2)
α:	73.09(7)°
ß:	71.79(6)°
Y:	84.63(6)°
V:	1641(2)
Z:	2

d) mycophenolate sodium methanol solvate;

crystal system:	triclinic
space group:	P-1
a:	7.761
b:	9.588
c:	14.094
α:	109.96°
ß:	95.99°
Y:	83.05°
V:	976.3
Z:	2

e) mycophenolate sodium methanol solvate II;

crystal system:	triclinic
space group:	P-1

a:	9.179
b:	10.724
c:	12.098
α:	113.27 °
ß:	101.76 °
Y:	104.44 °
V:	996.4
Z:	2

f) mycophenolate disodium salt, monohydrate;
having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 6;

g) mycophenolate disodium salt, pentahydrate;

crystal system:	monoclinic
space group:	P 2_1/c,
a:	14.495
b:	17.613
c:	8.401
ß:	97.15 °
V:	2128
Z:	4

h) mycophenolic acid;

crystal system:	triclinic
space group:	P -1
a:	7.342
b:	9.552
c:	11.643
α:	102.70 °
ß:	90.89 °
Y:	90.74 °
V:	796.3
Z:	2

i) mycophenolate sodium hydrate form B;
having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 10;

j) mycophenolate sodium hydrate form C;
having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 12;

Claim 12. (New): A process according to claim 2 wherein the crystal habit is modified in that the mean aspect ratio of the processed crystals is smaller than about 10:1.

Claim 13. (New): A process according to claim 2 wherein the drug substance after temperature oscillation has a bulk density of about above 200 kg/m^3.

Claim 14. (New): A process according to claim 2 wherein the temperature oscillation is in form of a zig-zag curve.

Claim 15. (New): A process according to claim 2 wherein the crystals produced have a mean aspect ratio of the processed crystals smaller than about 10:1 or a bulk density of about 200 kg/m^3.

Claim 16. (New): A pharmaceutical composition in the form of tablets, comprising crystals of claim 2 in association with a pharmaceutically acceptable carrier.